Analysis of UK inhaler medicine use and carbon footprint presented at the British Thoracic Society Winter Meeting
英国呼吸吸入药物使用的新分析表明，83％的哮喘患者患有哮喘的哮喘症（SABA）患者的患者患者潜在过度覆盖救助药物。1The overuse of SABA relievers is responsible for 250,000 tonnes of CO2equivalent annually.1
这些调查结果将在英国胸部社会冬季会议上呈现，基于SABA处方，并在2007 - 2017年间统一的大规模观测研究中的SABA中英国研究中的英国研究中提取的数据，大规模观测研究中的统一计划。。2
每年三个或更多SABA吸入器的处方与哮喘控制差，大约是与低SABA用户（规定0-2吸入器/年）相比的加剧次数的两倍，并增加哮喘相关的医疗保健利用率。2,3哮喘是一种慢性，可变的炎症性疾病，影响英国（成人430万人），可引起哮喘的攻击和症状，包括呼吸困难和喘息。4,5Every 10 seconds someone in the UK has a potentially life-threatening asthma attack with, on average, three people dying from asthma every day.5
Alexander J K Wilkinson, Consultant in Respiratory and General Medicine, East and North Hertfordshire NHS Trust, Stevenage, UK and lead author of the study said: “Overuse of reliever inhalers in asthma is widespread in the UK and associated with an increased risk of exacerbations for patients, highlighting the importance of adopting strategies to improve disease control and reduce short-acting beta2-agonist overuse. This new analysis shows that reliever overuse is also a major contributor to greenhouse gas emissions in respiratory care, similar to driving an average diesel car for about 900 million miles. These findings are important for informing clinical guidelines and healthcare policies to support improvements in asthma care while also realising carbon savings.”
Alex de Giorgio-Miller, Vice President, Medical & Scientific Affairs, AstraZeneca UK, said: “We know that the overuse of SABA reliever inhalers is associated with an increased risk of severe asthma attacks, but this analysis highlights the scale of the problem we face in the UK, both in terms of poor health outcomes and the corresponding greenhouse gas burden. By reducing over-reliance on SABA inhalers and improving asthma outcomes, we can also have an important positive impact on the environment.”
分析的进一步取得了进一步的结果表明，SABA吸入器使用从英国的吸入器装置驱动70％的温室气体排放（GHG）。1人均使用英国的所有Saba Reliever吸入器的使用率大致高音或超过在其他大型欧洲国家观察到的，导致更高的温室气体排放。1
哮喘
哮喘是一种常见的慢性呼吸道疾病，它会影响到达全世界3.39亿个成年人和儿童的健康和日常生活。6它的特征在于经常发生的呼吸性和喘息，随着时间的推移而变化，以及人员的严重程度和频率。7
无论其疾病严重程度，依从治疗或对照水平，所有哮喘患者均面临严重恶化的风险。8,9,10There are an estimated 176 million asthma exacerbations globally per year;11对于许多患者来说，这些都是身体威胁和情绪重要意义。12然而，尽管哮喘是一种慢性，可变的炎症性疾病，但许多患者都被规定或不使用它们的抗炎维持治疗，并且可能过度依赖于其SABA缓解，这可以掩盖症状恶化。13-16在恶化症状期间单独服用SABA吸入器并未解决潜在的炎症，使患者患哮喘恶化的风险和潜在暴露于口腔皮质类固醇的频繁爆发。17
哮喘的全球倡议不再推荐萨巴作为首选的残废疗法服用。4每年的三个或更多SABA吸入器的处方与哮喘患者患者患者缺乏患者的风险增加以及住院。4
野心零碳
哮喘护理中最常见的缓解吸入器包括负责气候影响的温室气体排放的氢氟烷烃（HFA）推进剂。18欧洲杯微信买球阿斯利康致力于将其和atory inhalers containing HFA propellants to near-zero Global Warming Potential (GWP) propellants. The conversion to near-zero inhalers is part of AstraZeneca’s wider Ambition Zero Carbon programme, which aims to achieve zero carbon emissions from operations across the world by 2025 and to ensure our entire value chain is carbon negative by 2030, bringing forward decarbonisation plans by more than a decade.
在英国过度使用SABA负责每年250,000吨二氧化碳当量，该碳足迹类似于驾驶平均柴油车约9亿英里。1,19
萨娜
由Astrazeneca资助的哮喘（Sabina）全球计划的SABA是最大的真实世界分析与哮喘的SABA使用和维护治疗有欧洲杯微信买球关的临床结果，包括统一，大规模观测研究的创新框架40个国家。20
Sabina在全球范围内包括超过150万哮喘患者，有四个主要支柱：
- 萨娜I – Retrospective observational database study in the UK.
- Sabina II - 回顾性观测数据库研究在8个国家（法国，德国，意大利，荷兰，西班牙，瑞典，加拿大和以色列）。
- 萨娜III – Cross-sectional study conducted in 24 countries across 5 continents.
- 萨娜+ – Multi-design extended pillar for countries that joined after initiation of the programme (China, Hong Kong, Morocco, Poland, Romania, Switzerland, and the US).
Results from the SABINA programme published to date have shown that prescription or collection of three or more SABA inhalers per year is associated with poor asthma control, approximately twice the number of exacerbations compared with low SABA users (prescribed 0-2 inhalers/year) and increased asthma-related healthcare utilisation.2,3
在Sabina I中，对哮喘患者的SABA吸入器处方的分析表明，83％的患者每年患有三个或更多SABA吸入器的患者。1
欧洲杯微信买球Astrazeneca在呼吸系统和免疫学中
呼吸和免疫学是Astrazeneca的三个治疗领域之一，是该公司的主要欧洲杯微信买球增长司机。
Building on a 50-year heritage, AstraZeneca is an established leader in respiratory care across inhaled and biologic medicines. AstraZeneca aims to transform the treatment of asthma and chronic obstructive pulmonary disease (COPD) by eliminating preventable asthma attacks across all severities and removing COPD as leading cause of death through earlier, biology-led treatment. The Company’s early respiratory research is focused on emerging science involving immune mechanisms, lung damage and abnormal cell repair processes in disease and neuronal dysfunction.
随着呼吸和免疫学的常见途径和潜在的疾病司机，Astrazeneca正在追随慢性肺病的科学对免疫驱动的疾病。欧洲杯微信买球该公司在免疫学中增长的越来越多地关注五个中期的中期特许经营，具有风湿病的多疾病潜力（包括Systemic Lupus红斑狼疮），皮肤科，胃肠学和全身性嗜酸性嗜酸性疾病。欧洲杯微信买球Astrazeneca在免疫学的野心是在靶向免疫驱动疾病中实现疾病控制和最终临床缓解。
欧洲杯微信买球
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visitastrazeneca.com并在Twitter上遵循公司@欧洲杯微信买球。
References
1. Wilkinson AJK, Menzies-Gow A, Sawyer M,等。An assessment of short-acting β2-agonist (SABA) use and subsequent greenhouse gas (GHG) emissions in five European countries and the consequence of their potential overuse for asthma in the U.K. BTS Oral Abstract No: S26.http://dx.doi.org/10.1136/thorax-2020-BTSabstracts.32
2. Bloom Ci，Cabrera C，Arnetorp S，等。哮喘相关的健康结果与短作用β2激动剂吸入器使用：一个观察英国作为Sabina Global计划的一部分。adv ther2020;37: 4190–4208.
3. nwaru bi，ekströmm，hasvold p，等。过度使用哮喘短作用β2激动剂与加剧和死亡率的风险增加有关：全球萨宾纳计划的全国队列研究。Eur Respir J。2020;55（4）：1901872。
4.哮喘的全球倡议。2020吉娜报告，哮喘管理和预防的全球战略。[在线的]。可用于：https://ginasthma.org/gina-reports/。[Last accessed: 1 Feb 2021]
5.哮喘的事实和统计数据。[在线]可用：https://www.asthma.org.uk/about/media/facts-and-statistics/。[Last accessed: 1 Feb 2021]
6. The Global Asthma Network. The Global Asthma Report 2018. [Online]. Available at:http://www.globalasthManetWork.org/。[最后访问：2月1日2月1日]。
7. National Heart, Lung, and Blood Institute. Guidelines for the Diagnosis and Management of Asthma (EPR-3). [Online]. Available at:https://www.nhlbi.nih.gov/health-topics/guidelines-for-diagnosis-management-of-asthma.。[最后访问：2月1日2月1日]。
8.奥加利贝尔JM，Quirce S，Julia B，等。根据哮喘指南全球倡议测量哮喘控制：与哮喘控制问卷的比较。Respir Res.201; 13: 50.
9.价格D，Fletcher M，Van der Molen T.哮喘控制和管理在8,000名欧洲患者中：识别哮喘并链接症状和经验（实现）调查。NPJ Prim Care Respir Med.2014;24：14009。
10. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary.Eur Respir J.2008;31：143-78。
11. 欧洲杯微信买球Astazeneca药品。文件上的数据。Budesonide / Formoterol：全球癌症的年度加剧（ID：SD-3010-al-0017）。
12. Sastre J, Fabbri LM, Price D,等等。Insights, attitudes, and perceptions about asthma and its treatment: a multinational survey of patients from Europe and Canada.世界过敏器官J.2016; 9: 13.
13. Humbert M, Andersson TL, Buhl R. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.过敏。2008;63：1567-80。
14. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the asthma insights and reality in Europe (AIRE) study.Eur Respir J.2000;16：802-7。
15. Tattersfield AE，邮政DS，Barnes PJ，等。on behalf of the FACET International Study Group. Exacerbations of asthma: a descriptive study of 425 severe exacerbations.Am J Respir Crit Care Med.1999;160：594-9。
16. Adams RJ，Fuhlbrigge A，Guilbert T，等。Inadequate use of asthma medication in the United States: results of the asthma in America national population survey.j alerergy inlmunol。2002;110：58-64。
17. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study.J Asthma Allergy.2018;11：193-204。
18. Panigone S，Sandri F，Ferri R，等。吸入器对呼吸系统疾病的环境影响：降低碳足迹，同时保持患者量身定制的治疗。BMJ Open Respir Res。2020;7（1）：E000571。
19. Guidance on how to measure and report your greenhouse gas emissions. [Online] Available fromhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/Attachment_Data/File/69282/PB13309-ghg-guidance-0909011.pdf.[最后访问：2月1日2月1日]。
20. Cabrera CS, Nan C, Lindarck N,等。Sabina：全球计划评估与哮喘短发β2激动剂使用相关的处方和临床结果。Eur Respir J。2020;55（2）：1901858。
Veeva ID: Z4-30765
Date of Preparation: February 2021